nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2017-21-4-48-54nefr-278Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESУСЛОВИЯ РАЗВИТИЯ УРАТНОГО НЕФРОЛИТИАЗА И ПОДХОДЫ К ЕГО МОДЕЛИРОВАНИЮCONDITIONS OF URATE NEPHROLITHIASIS AND APPROACHES TO ITS MODELINGПерфильевВ. Ю.PerfilevV. Yu.1991PS@mail.ruЗверевЯ. Ф.ZverevYa. F.

Проф., д-р мед. наук

Prof., DMedSci.

zver@asmu.ruЖариковА. Ю.ZharikovA. Yu.

Проф., д-р биол. наук

Prof., DBiolSci.

zharikov@agmu.ruКафедра фармакологии Алтайского государственного медицинского университетаРоссияDepartment pharmacology, Altai State Medical UniversityRussian Federation2017050720172144854Copyright © Перфильев В.Ю., Зверев Я.Ф., Жариков А.Ю., 20172017Перфильев В.Ю., Зверев Я.Ф., Жариков А.Ю.Perfilev V.Y., Zverev Y.F., Zharikov A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/278

В обзоре описаны патофизиологические факторы, способствующие развитию уратного нефролитиаза. Представлены различные подходы к его моделированию. Отмечены наиболее выгодные методики с позиции современных представлений о патогенезе заболевания.

The review describes the pathophysiological factors that contribute to the development of uric acid nephrolithiasis. Different approaches to its modeling are presented. Noted the most favorable methods from the standpoint of modern concepts of the disease pathogenesis.

уратная нефропатиямодель уратного нефролитиазаUrate nephropathymodel urate nephrolithiasisReferencesBobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Advances in chronic kidney disease 2012; 19 (6): 358-371Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Advances in chronic kidney disease 2012; 19 (6): 358-371Wu X et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. Journal of molecular evolution 1992; 34 (1): 78-84Wu X et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. Journal of molecular evolution 1992; 34 (1): 78-84Alvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology 2010; 49 (11): 2010-2015Alvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology 2010; 49 (11): 2010-2015Doherty M. New insights into the epidemiology of gout. Rheumatology 2009; 48: ii2-ii8Doherty M. New insights into the epidemiology of gout. Rheumatology 2009; 48: ii2-ii8Пытель ЮА, Золотарев ИИ. Уратный нефролитиаз. Медицина, М., 1995; 176 c [Pytel’ YUA, Zolotarev II. Uratnyj nefrolitiaz. M.: Medicina, 1995; 176 s]Пытель ЮА, Золотарев ИИ. Уратный нефролитиаз. Медицина, М., 1995; 176 c [Pytel’ YUA, Zolotarev II. Uratnyj nefrolitiaz. M.: Medicina, 1995; 176 s]Burns CM, Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Faci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Principles of Internal Medicine, McGraw-Hill, New York, 2012: 215-219Burns CM, Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Faci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Principles of Internal Medicine, McGraw-Hill, New York, 2012: 215-219Kratzer JT, Lanaspa MA, Murphy MN et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 2014; 111 (10): 3763-3768Kratzer JT, Lanaspa MA, Murphy MN et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 2014; 111 (10): 3763-3768Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis The Lancet Neurology 2015; 14 (2): 183-193Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis The Lancet Neurology 2015; 14 (2): 183-193Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795Зверев ЯФ, Брюханов ВМ. Современный взгляд на механизмы развития уратного нефролитиаза. Клин нефролог 2015; (5-6): 39-47 [Zverev YaF, Bryuhanov VM. Sovremennyj vzglyad na mekhanizmy razvitiya uratnogo nefrolitiaza. Klin nefrolog 2015; (5-6): 39-47]Зверев ЯФ, Брюханов ВМ. Современный взгляд на механизмы развития уратного нефролитиаза. Клин нефролог 2015; (5-6): 39-47 [Zverev YaF, Bryuhanov VM. Sovremennyj vzglyad na mekhanizmy razvitiya uratnogo nefrolitiaza. Klin nefrolog 2015; (5-6): 39-47]Брюханов ВМ, Зверев ЯФ, Лампатов ВВ. и др. Влияние питьевых режимов на движущие силы кристаллизации при экспериментальном нефролитиазе. Урология 2011; 1: 6-11 [Bryuhanov VM, Zverev YAF, Lampatov VV i dr. Vliyanie pit’evyh rezhimov na dvizhushchie sily kristallizacii pri ehksperimental’nom nefrolitiaze. Urologiya 2011; 1: 6-11]Брюханов ВМ, Зверев ЯФ, Лампатов ВВ. и др. Влияние питьевых режимов на движущие силы кристаллизации при экспериментальном нефролитиазе. Урология 2011; 1: 6-11 [Bryuhanov VM, Zverev YAF, Lampatov VV i dr. Vliyanie pit’evyh rezhimov na dvizhushchie sily kristallizacii pri ehksperimental’nom nefrolitiaze. Urologiya 2011; 1: 6-11]Зверев ЯФ, Брюханов ВМ, Лампатов ВВ, Жариков АЮ. Современные представления о роли физико-химических факторов в патогенезе кальциевого нефролитиаза. Нефрология 2009; 13 (1): 39-50 [Zverev YAF, Bryuhanov VM, Lampatov VV, ZHarikov AYU. Sovremennye predstavleniya o roli fiziko-himicheskih faktorov v patogeneze kal’cievogo nefrolitiaza. Nefrologiya 2009; 13 (1): 39-50]Зверев ЯФ, Брюханов ВМ, Лампатов ВВ, Жариков АЮ. Современные представления о роли физико-химических факторов в патогенезе кальциевого нефролитиаза. Нефрология 2009; 13 (1): 39-50 [Zverev YAF, Bryuhanov VM, Lampatov VV, ZHarikov AYU. Sovremennye predstavleniya o roli fiziko-himicheskih faktorov v patogeneze kal’cievogo nefrolitiaza. Nefrologiya 2009; 13 (1): 39-50]Atan L et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65 (5): 858-861Atan L et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65 (5): 858-861Robertson WG. Renal stones in the tropics. Seminars in nephrology 2003; 23 (1): 77-87Robertson WG. Renal stones in the tropics. Seminars in nephrology 2003; 23 (1): 77-87Yu TF, Gutman A.B. Uric acid nephrolithiasis in gout. Annals of internal medicine 1967; 67 (6): 1133-1148Yu TF, Gutman A.B. Uric acid nephrolithiasis in gout. Annals of internal medicine 1967; 67 (6): 1133-1148Барскова ВГ, Мукагова МВ. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Современная ревматология 2011; 4: 39-43 [Barskova VG, Mukagova MV. Sovremennye predstavleniya o patogeneze i metodah korrekcii uratnogo nefrolitiaza u bol’nyh podagroj. Sovremennaya revmatologiya 2011; 4: 39-43]Барскова ВГ, Мукагова МВ. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Современная ревматология 2011; 4: 39-43 [Barskova VG, Mukagova MV. Sovremennye predstavleniya o patogeneze i metodah korrekcii uratnogo nefrolitiaza u bol’nyh podagroj. Sovremennaya revmatologiya 2011; 4: 39-43]Alvarez-Nemegyei J et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? The Journal of rheumatology 2005; 32 (11): 2189-2191Alvarez-Nemegyei J et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? The Journal of rheumatology 2005; 32 (11): 2189-2191Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. American Journal of Kidney Diseases 2002; 40 (1): 37-42Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. American Journal of Kidney Diseases 2002; 40 (1): 37-42Kramer HJ et al. The association between gout and nephrolithiasis in men: The Health Professionals’ Follow-Up Study. Kidney international 2003; 64 (3): 1022-1026Kramer HJ et al. The association between gout and nephrolithiasis in men: The Health Professionals’ Follow-Up Study. Kidney international 2003; 64 (3): 1022-1026Davidson MB et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. The American journal of medicine 2004; 116 (8): 546-554Davidson MB et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. The American journal of medicine 2004; 116 (8): 546-554Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Current rheumatology reports 2007; 9 (3) 251-257Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Current rheumatology reports 2007; 9 (3) 251-257Руденская ГЕ, Захарова ЕЮ, Бессонова ЛА и др. Синдром Леша-Найхана: фенотипическое разнообразие и ДНК-диагностика. Медицинская генетика 2010; 9 (9): 41-48 [Rudenskaya GE, Zaharova EYU, Bessonova LA i dr. Sindrom Lesha-Najhana: fenotipicheskoe raznoobrazie i DNK-diagnostika. Medicinskaya genetika 2010; 9 (9): 41-48]Руденская ГЕ, Захарова ЕЮ, Бессонова ЛА и др. Синдром Леша-Найхана: фенотипическое разнообразие и ДНК-диагностика. Медицинская генетика 2010; 9 (9): 41-48 [Rudenskaya GE, Zaharova EYU, Bessonova LA i dr. Sindrom Lesha-Najhana: fenotipicheskoe raznoobrazie i DNK-diagnostika. Medicinskaya genetika 2010; 9 (9): 41-48]Ngo TC, Assimos DG. Uric acid nephrolithiasis: recent progress and future directions. Reviews in urology 2007; 9 (1): 17Ngo TC, Assimos DG. Uric acid nephrolithiasis: recent progress and future directions. Reviews in urology 2007; 9 (1): 17Talente GM et al. Glycogen storage disease in adults. Annals of internal medicine 1994; 120 (3): 218-226Talente GM et al. Glycogen storage disease in adults. Annals of internal medicine 1994; 120 (3): 218-226Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency: the molecular basis of the clinical syndromes. New England Journal of Medicine 1983; 309 (15): 900-910Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency: the molecular basis of the clinical syndromes. New England Journal of Medicine 1983; 309 (15): 900-910Tsimberidou A, Keating MJ. Hyperuricemic syndromes in cancer patients Hyperuricemic Syndromes: Pathophysiology and Therapy. Karger Publishers, 2004; 147: 47-60Tsimberidou A, Keating MJ. Hyperuricemic syndromes in cancer patients Hyperuricemic Syndromes: Pathophysiology and Therapy. Karger Publishers, 2004; 147: 47-60Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacology & therapeutics 2012; 136 (1): 106-130Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacology & therapeutics 2012; 136 (1): 106-130Mullin JW. Nucleation. In: Crystallization. ButterworthHeinemann, Oxford. 1993; 172-201Mullin JW. Nucleation. In: Crystallization. ButterworthHeinemann, Oxford. 1993; 172-201Anzai N et al. Recent advances in renal urate transport: characterization of candidate transporters indicated by genomewide association studies. Clinical and experimental nephrology 2012; 16 (1): 89-95Anzai N et al. Recent advances in renal urate transport: characterization of candidate transporters indicated by genomewide association studies. Clinical and experimental nephrology 2012; 16 (1): 89-95Lipkowitz MS. Regulation of uric acid excretion by the kidney. Current rheumatology reports 2012; 14 (2): 179-188Lipkowitz MS. Regulation of uric acid excretion by the kidney. Current rheumatology reports 2012; 14 (2): 179-188So A, Thorens B. Uric acid transport and disease. The Journal of clinical investigation 2010; 120 (6): 1791-1799So A, Thorens B. Uric acid transport and disease. The Journal of clinical investigation 2010; 120 (6): 1791-1799Bach MH, Simkin PA. Uricosuric drugs: the once and future therapy for hyperuricemia? Current opinion in rheumatology 2014; 26 (2): 169-175Bach MH, Simkin PA. Uricosuric drugs: the once and future therapy for hyperuricemia? Current opinion in rheumatology 2014; 26 (2): 169-175Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides, Nucleotides, and Nucleic Acids 2008; 27 (6-7): 578-584Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides, Nucleotides, and Nucleic Acids 2008; 27 (6-7): 578-584Richette P, Garay R. Novel drug discovery strategies for gout. Expert opinion on drug discovery 2013; 8 (2): 183-189Richette P, Garay R. Novel drug discovery strategies for gout. Expert opinion on drug discovery 2013; 8 (2): 183-189Torralba KD, Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. International journal of rheumatic diseases 2012; 15 (6): 499-506Torralba KD, Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. International journal of rheumatic diseases 2012; 15 (6): 499-506Villegas R et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutrition, Metabolism and Cardiovascular Diseases 2012; 22 (5): 409-416Villegas R et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutrition, Metabolism and Cardiovascular Diseases 2012; 22 (5): 409-416Кадыров ЗА, Истратов ВГ, Сулейманов СИ. Некоторые вопросы этиологии и патогенеза мочекаменной болезни. Урология 2006; 5: 98-102 [Kadyrov ZA, Istratov VG, Sulejmanov SI. Nekotorye voprosy ehtiologii i patogeneza mochekamennoj bolezni. Urologiya 2006; 5: 98-102]Кадыров ЗА, Истратов ВГ, Сулейманов СИ. Некоторые вопросы этиологии и патогенеза мочекаменной болезни. Урология 2006; 5: 98-102 [Kadyrov ZA, Istratov VG, Sulejmanov SI. Nekotorye voprosy ehtiologii i patogeneza mochekamennoj bolezni. Urologiya 2006; 5: 98-102]Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Current rheumatology reports 2014; 16 (2): 1-8Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Current rheumatology reports 2014; 16 (2): 1-8Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC, ed. Campbell’s Urology, 8th ed. Saunders, Philadelphia. 2002; 3229-3305Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC, ed. Campbell’s Urology, 8th ed. Saunders, Philadelphia. 2002; 3229-3305Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney international 2009; 75 (6): 585-595Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney international 2009; 75 (6): 585-595Вандер А. Физиология почек. Под ред. Ю.В.Наточина (Пер с англ. Г.А. Лаписа), Питер, СПб., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256. [Vander A. Fiziologiya pochek. Pod red. YU.V.Natochina (Per s angl. G.A. Lapisa), Piter, SPb., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256.]Вандер А. Физиология почек. Под ред. Ю.В.Наточина (Пер с англ. Г.А. Лаписа), Питер, СПб., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256. [Vander A. Fiziologiya pochek. Pod red. YU.V.Natochina (Per s angl. G.A. Lapisa), Piter, SPb., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256.]Kamel KS, Cheema-Dhadli S, Halperin ML. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney international 2002; 61 (3): 988-994Kamel KS, Cheema-Dhadli S, Halperin ML. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney international 2002; 61 (3): 988-994Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney int 2002; 62(3): 971-979Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney int 2002; 62(3): 971-979Minkowski O. Untersuchungen zur Physiologie und Pathologie der Harnsäure bei Säugethieren. Archiv für experimentelle Pathologie und Pharmakologie 1898; 41 (6): 375-420Minkowski O. Untersuchungen zur Physiologie und Pathologie der Harnsäure bei Säugethieren. Archiv für experimentelle Pathologie und Pharmakologie 1898; 41 (6): 375-420Bendich A et al. The direct oxidation of adenine in vivo. Journal of Biological Chemistry 1950; 183 (1): 267-277Bendich A et al. The direct oxidation of adenine in vivo. Journal of Biological Chemistry 1950; 183 (1): 267-277Simmonds HA, Van Acker KJ. Adenine phosphoribosyltransferase deficiency: 2, 8-dihydroxyadenine lithiasis. Metabolic basis of inherited disease Edited by John B. Stanbury et al. 1983Simmonds HA, Van Acker KJ. Adenine phosphoribosyltransferase deficiency: 2, 8-dihydroxyadenine lithiasis. Metabolic basis of inherited disease Edited by John B. Stanbury et al. 1983Yokozawa T et al. Adenine-induced hyperuricemia and renal damage in rats. Journal of the agricultural chemical society of japan 1982; 56 (8): 655-663Yokozawa T et al. Adenine-induced hyperuricemia and renal damage in rats. Journal of the agricultural chemical society of japan 1982; 56 (8): 655-663Yokozawa T et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44 (3): 230-234Yokozawa T et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44 (3): 230-234Yokozawa T et al. Influence of dietary purine on the level of uric acid in the serum and urine. J Jpn Soc Food Nutr 1981; 34: 35-41Yokozawa T et al. Influence of dietary purine on the level of uric acid in the serum and urine. J Jpn Soc Food Nutr 1981; 34: 35-41Yokozawa T et al. Metabolic effects of dietary adenine in rats Journal of the Agricultural Chemical Society of Japan 1981Yokozawa T et al. Metabolic effects of dietary adenine in rats Journal of the Agricultural Chemical Society of Japan 1981Yokozawa T et al. Metabolic effects of dietary purine and pyrimidine bases in rats. Agricultural and biological chemistry 1983; 47 (6): 1297-1304Yokozawa T et al. Metabolic effects of dietary purine and pyrimidine bases in rats. Agricultural and biological chemistry 1983; 47 (6): 1297-1304Yokozawa T, Oura H, Koizumi F 2, 8-Dihydroxyadenine urolithiasis induced by dietary adenine in rats. Nihon Jinzo Gakkai shi 1985; 27 (3): 371-378Yokozawa T, Oura H, Koizumi F 2, 8-Dihydroxyadenine urolithiasis induced by dietary adenine in rats. Nihon Jinzo Gakkai shi 1985; 27 (3): 371-378Yokozawa T, Zheng PD, Oura H. Biochemical features induced by adenine feeding in rats. Polyuria, electrolyte disorders, and 2, 8-dihydroxyadenine deposits. Journal of nutritional science and vitaminology 1984; 30 (3): 245-254Yokozawa T, Zheng PD, Oura H. Biochemical features induced by adenine feeding in rats. Polyuria, electrolyte disorders, and 2, 8-dihydroxyadenine deposits. Journal of nutritional science and vitaminology 1984; 30 (3): 245-254Diwan V et al. Adenine-induced chronic kidney and cardiovascular damage in rats. Journal of pharmacological and toxicological methods 2013; 68 (2): 197-207Diwan V et al. Adenine-induced chronic kidney and cardiovascular damage in rats. Journal of pharmacological and toxicological methods 2013; 68 (2): 197-207Adachi S, Yoshizawa F, Yagasaki K. Assay systems for screening food and natural substances that have anti-hyperuricemic activity: uric acid production in cultured hepatocytes and purine bodies-induced hyperuricemic model mice. Cytotechnology 2016; 1-8Adachi S, Yoshizawa F, Yagasaki K. Assay systems for screening food and natural substances that have anti-hyperuricemic activity: uric acid production in cultured hepatocytes and purine bodies-induced hyperuricemic model mice. Cytotechnology 2016; 1-8Epstein FH, Pigeon G. Experimental urate nephropathy: studies of the distribution of urate in renal tissue. Nephron 1964; 1 (3): 144-157Epstein FH, Pigeon G. Experimental urate nephropathy: studies of the distribution of urate in renal tissue. Nephron 1964; 1 (3): 144-157Stavric B, Johnson WJ, Grice HC. Uric Acid Nephropathy An Experimental Model. Experimental Biology and Medicine 1969; 130 (2): 512-516Stavric B, Johnson WJ, Grice HC. Uric Acid Nephropathy An Experimental Model. Experimental Biology and Medicine 1969; 130 (2): 512-516Stavric B et al. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor. Investigative urology 1973; 11 (1): 3Stavric B et al. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor. Investigative urology 1973; 11 (1): 3Waisman J et al. Acute hyperuricemic nephropathy in rats. An electron microscopic study. The American journal of pathology 1975; 81 (2): 367Waisman J et al. Acute hyperuricemic nephropathy in rats. An electron microscopic study. The American journal of pathology 1975; 81 (2): 367Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. Arthritis & Rheumatism 1975; 18 (2): 153-165Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. Arthritis & Rheumatism 1975; 18 (2): 153-165Schumacher HR, Phelps P, Agudelo CA. Urate crystal induced inflammation in dog joints: sequence of synovial changes. The Journal of rheumatology 1974; 1 (1): 102Schumacher HR, Phelps P, Agudelo CA. Urate crystal induced inflammation in dog joints: sequence of synovial changes. The Journal of rheumatology 1974; 1 (1): 102Schumacher HR, Phelps P. Sequential changes in human polymorphonuclear leukocytes after urate crystal phagocytosis. An electron microscopic study. Arthritis & Rheumatism 1971; 14 (4): 513-526Schumacher HR, Phelps P. Sequential changes in human polymorphonuclear leukocytes after urate crystal phagocytosis. An electron microscopic study. Arthritis & Rheumatism 1971; 14 (4): 513-526Kim YG et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Molecular Medicine 2000; 6 (10): 837Kim YG et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Molecular Medicine 2000; 6 (10): 837Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008; 359 (17): 1811-1821Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008; 359 (17): 1811-1821Mazzali M et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38 (5): 1101-1106Mazzali M et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38 (5): 1101-1106Mazzali M et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. American Journal of Physiology-Renal Physiology 2002; 282 (6): F991-F997Mazzali M et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. American Journal of Physiology-Renal Physiology 2002; 282 (6): F991-F997Wang R et al. Siwu decoction attenuates oxonate-induced hyperuricemia and kidney inflammation in mice. Chinese Journal of Natural Medicines 2016; 14 (7): 499-507Wang R et al. Siwu decoction attenuates oxonate-induced hyperuricemia and kidney inflammation in mice. Chinese Journal of Natural Medicines 2016; 14 (7): 499-507Wu X et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proceedings of the National Academy of Sciences 1994; 91 (2): 742-746Wu X et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proceedings of the National Academy of Sciences 1994; 91 (2): 742-746Халфина ТН, Максудова АН, Абдракипов РЗ. Современный взгляд на патогенетические механизмы гиперурикемии. Практическая медицина 2012; 8 (64): 66-67 [Halfina TN, Maksudova AN, Abdrakipov RZ. Sovremennyj vzglyad na patogeneticheskie mekhanizmy giperurikemii. Prakticheskaya medicina 2012; 8 (64): 66-67]Халфина ТН, Максудова АН, Абдракипов РЗ. Современный взгляд на патогенетические механизмы гиперурикемии. Практическая медицина 2012; 8 (64): 66-67 [Halfina TN, Maksudova AN, Abdrakipov RZ. Sovremennyj vzglyad na patogeneticheskie mekhanizmy giperurikemii. Prakticheskaya medicina 2012; 8 (64): 66-67]Martín NE, Nieto VG. Hypouricemia and tubular transport of uric acid. Nefrologia 2011; 31 (1): 44-50Martín NE, Nieto VG. Hypouricemia and tubular transport of uric acid. Nefrologia 2011; 31 (1): 44-50Berliner RW et al. The renal mechanism for urate excretion in man. Journal of Clinical Investigation 1950; 29 (4): 396Berliner RW et al. The renal mechanism for urate excretion in man. Journal of Clinical Investigation 1950; 29 (4): 396Gutman AB, Yu TF. A three-component system for regulation of renal excretion of uric acid in man. Transactions of the Association of American Physicians 1961; 74: 353Gutman AB, Yu TF. A three-component system for regulation of renal excretion of uric acid in man. Transactions of the Association of American Physicians 1961; 74: 353Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system. Annals of the rheumatic diseases 1980; 39 (2): 173-179Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system. Annals of the rheumatic diseases 1980; 39 (2): 173-179Anzai N et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. Journal of Biological Chemistry 2008; 283 (40): 26834-26838Anzai N et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. Journal of Biological Chemistry 2008; 283 (40): 26834-26838Bibert S et al. Mouse GLUT9: evidences for a urate uniporter. American Journal of Physiology-Renal Physiology 2009; 297 (3): F612-F619Bibert S et al. Mouse GLUT9: evidences for a urate uniporter. American Journal of Physiology-Renal Physiology 2009; 297 (3): F612-F619Preitner F et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proceedings of the National Academy of Sciences 2009; 106 (36): 15501-15506Preitner F et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proceedings of the National Academy of Sciences 2009; 106 (36): 15501-15506Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795Feig DI et al. Serum uric acid: a risk factor and a target for treatment? Journal of the American Society of Nephrology 2006; 17 (4): S69-S73Feig DI et al. Serum uric acid: a risk factor and a target for treatment? Journal of the American Society of Nephrology 2006; 17 (4): S69-S73

The authors declare that there are no conflicts of interest present.